Navigation Links
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Date:6/8/2009

e in most patients.

If patients experience the following severe and persistent symptoms (alone or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should talk to their healthcare provider because these symptoms could be signs of serious medical conditions. BYETTA may reduce appetite, the amount of food eaten, and body weight. No changes in dose are needed for these side effects. These are not all of the side effects from use of BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away. For full prescribing information, visit www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit, www.lillydiabetes.com.

'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nurse Scholar-in Residence at the Institute of Medicine (IOM) of the National Academies. ... at Columbia University School of Nursing. A member of the Institute of Medicine ...
(Date:9/1/2015)... ... 01, 2015 , ... Ogawa’s new massage chairs tout innovative functionality that change ... than ever before. With the goal of bringing wellness to the world, Ogawa introduces ... , As in its name, the Ogawa Refresh aims to “refresh” ...
(Date:9/1/2015)... Aventura, Florida (PRWEB) , ... September 01, 2015 ... ... across language barriers and international borders seldom arise at the most convenient time ... which is always ready to help. , Universal Translation Services has ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2
... volunteers for HIV/AIDS research in the United States and ... that the forms were extremely long and used wording ... understanding, according to bioethicists at The Johns Hopkins University. ... U.S. government-sponsored, multinational HIV/AIDS research conducted in 2006 revealed ...
... THURSDAY, July 14 (HealthDay News) -- A novel version ... and animals has managed to jump from one species and ... virus is from the adenovirus family, responsible for the common ... now -- unlike other types of viruses -- these particular ...
... July 14, 2011) In a study, Identification of ... in the July 2011 issue of the Journal ... of Dental Medicine found that dental visits represented a ... individuals with diabetes or pre-diabetes who are unaware of ...
... , THURSDAY, July 14 (HealthDay News) -- Military veterans who ... suicide attempt, but have an overall heightened risk of death ... study, published online in BioMed Central Public Health , ... seen at a Veterans Affairs medical center for a suicide ...
... Reporter , WEDNESDAY, July 13 (HealthDay News) -- Top ... air traffic controllers napping on the job are missing ... Studies have shown that short "power naps" have ... for people impaired by drowsiness, said Dr. Alon Avidan, ...
... cost-effective for treating people who are severely obese, but also ... study from Washington University School of Medicine in St. Louis. ... people, the researchers say. Patients who have the surgery ... have fewer medical problems related to their weight, indicating the ...
Cached Medicine News:Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 2Health News:Informed-consent forms should be shortened, simplified, Johns Hopkins bioethicists confirm 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 2Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 4Health News:Dentists can identify people with undiagnosed diabetes, Columbia researchers show 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 2Health News:Sometimes Sleeping on the Job May Be a Good Thing 3Health News:Weight-loss surgery cost-effective for all obese 2Health News:Weight-loss surgery cost-effective for all obese 3
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: